Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | BCR | P11274 | 1/20 | 0.61 |
| ▸ | PRKCA | P17252 | 1/20 | 0.61 |
| ▸ | IGF1R | P08069 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | IKBKB | O14920 | 1/20 | 0.56 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 3/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 2/20 | 0.51 |
| ▸ | CDK4 | P11802 | 2/20 | 0.51 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.50 |
| ▸ | RHOA | P61586 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4810750 | 0.93 | CDK2 (0.70) | CDK2ABL1BCRPRKCAIGF1R | |
| SCHEMBL16540727 | 0.91 | CDK2 (0.70) | CDK2IGF1RIRAK4AURKAMAPK8 | |
| SCHEMBL699041 | 0.90 | CDK2 (0.68) | CDK2ABL1BCRPRKCAIGF1R | |
| SCHEMBL10251812 | 0.89 | CDK2 (0.67) | CDK2ABL1BCRPRKCAIGF1R | |
| SCHEMBL7978513 | 0.89 | CDK2 (0.69) | CDK2IGF1RIKBKBIRAK4AURKA | |
| SCHEMBL17943211 | 0.86 | CDK2 (0.77) | CDK2ABL1PRKCAIGF1RNPC1 | |
| SCHEMBL4805850 | 0.85 | CDK2 (0.68) | CDK2IGF1RIRAK4MAPK8MAPK9 | |
| SCHEMBL699239 | 0.84 | HDAC1 (0.69) | CDK2ABL1BCRPRKCAIGF1R | |
| SCHEMBL16550119 | 0.83 | CDK2 (0.77) | CDK2ABL1BCRIGF1RIRAK4 | |
| SCHEMBL1684802 | 0.83 | CDK2 (1.00) | CDK2ABL1BCRPRKCAIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3039015-B1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-3039015-B1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2019-10-30 | — | — | EP | disclosed |
| US-10370371-B2 | Substituted pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370371-B2 | Substituted pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20160214978-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160214978-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| EP-3039015-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC Therapeutics, Inc. (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015030847-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-03-05 | — | — | WO | disclosed |
| WO-2015030847-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-03-05 | — | — | WO | disclosed |
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370371-B2 | Substituted pyrimidine Bmi-1 inhibitors | BMI1, BAZ2A, BRPF3 | CDK2 1121/4885ABL1 1707/4885BCR 733/4885 |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | CDK2 16/4885ABL1 1685/4885BCR 1488/4885 |
| US-20160214978-A1 | SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS | BMI1, BAZ2A, BRPF3 | CDK2 1121/4885ABL1 1707/4885BCR 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.